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The kidney has one of the richest and most diversified endothelial cell (EC) populations 
found within any organ. This extensive diversity can be explained on two counts. First, renal 
endothelium contributes to differential transport capabilities across the various segments of 
the nephron. Second, the endothelium must withstand unparalleled environment extremes in 
oxygenation and osmolality. Endothelial cells (ECs) in the outer cortex are exposed to 
normal osmolality and oxygen tension, whereas those in the inner medullary region are 
exposed to an osmolality of up to 1,200 mOSM and O2 content as low as 20 mm Hg.
Though significant progress has been done in the field of endothelial biology, still we know 
little about the different endothelial populations within kidney and the molecular mechanism 
that govern their structure, functions and potential injury. Therefore the goal of the review is 
to summarize the current knowledge concerning ECs in kidney and delineate the role of ECs 
under physiological and pathophysiological state especially in sepsis.
Structure and function
The unique structure of the vascular tree within the kidney is shown in the Figure 1. 
Anatomically, the kidney is divided into four zones. The cortex, occupies the outermost 
aspect of the kidney. As one moves toward the renal pelvis from the cortex, one encounters 
the outer medullary region, consisting of outer and inner stripes, and finally the inner 
medullary region. Although the renal arteries enter the kidney via the inner renal pelvis, a 
series of large branching arteries deliver arteriolar blood into the outer cortex via the 
interlobular arteries terminating in a network of glomerular afferent arterioles. Although the 
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overall blood flow to the kidney averages 4mL/g tissue/min, there is great heterogeneity 
within the kidney. The outer cortex receives 5–6mL/g/min with consecutively deeper areas 
receiving less flow per unit weight. The inner aspect of the cortex, outer medulla and inner 
medulla receive 2–3, 1, and 0.5 mL/g/min, respectively. Thus 90% of the blood flow is 
directed to the cortical area. The vast majority of blood flow reaches the medulla through 
juxtamedullary efferent arterioles; however, some may also be from periglomerular shunt 
pathways [1]. Afferent arterioles have a continuous smooth muscle layer and are the major 
resistance vessels controlling the glomerular filtration rate (GFR). They terminate to form 
the glomerular capillary network where formation of the primary urine takes place via 
filtration. Each glomerular capillary network gives rise to a single efferent arteriole. In 
contrast to their afferent counterpart, efferent arterioles have a limited discontinuous layer of 
smooth muscle cells.
Efferent arterioles follow one of the two paths. First, those that arise from glomeruli within 
the mid and outer cortex give rise to an O2-rich, dense network of capillaries (peritubular 
plexus) that run alongside the proximal and distal convoluted tubules in the kidney. This 
arrangement forms a unique vasculature where two capillary beds (glomerular and 
peritubular capillaries) are connected by an arteriole. Second, those efferent arterioles that 
arise from the innermost or juxtamedullary glomeruli give rise to the vasa recta, which run 
parallel to the loops of Henle and collecting tubules in the medulla. Descending arteriolar 
vasa recta branch into several vessels that penetrate the inner depths of the medulla, give rise 
to a dense capillary network within the inner medulla, and return to the cortex via venous 
ascending vasa recta (AVR). Descending vasa recta (DVR) and AVR, pack together in 
vascular bundles in the outer medulla, are the sole blood supply to the medulla.
The unique vascular architecture of the kidney results in a gradient of decreasing 
oxygenation from the cortex to the medulla. This arrangement is essential for development 
of the countercurrent mechanism necessary for the recycling of osmotic compounds to 
maintain the marked osmotic gradient that increases as one goes from the other cortex to the 
inner medullary region [2]. The density of the vascular space within the kidney also varies 
between the cortex and medullary regions. Traditionally, microvascular space has been 
considered as part of renal interstitium as H&E stain don’t identify ECs and thus one can’t 
differentiate the microvascular area from the true interstitial space. ECs within this 
heterogeneous microvasculature system also vary tremendously structurally and functionally 
depending upon location (Table 1). Afferent arterioles, with a mean pressure of 90mm Hg, 
give rise to glomerular capillaries that are lined by fine fenestrated endothelium and have a 
mean pressure of 60mm Hg. Diaphragms don’t not extend across these fenestrae and the 
fenestrae are surrounded by microfilaments [3]. Glomerular ECs are known to synthesize 
both nitric oxide (NO) and endothelin-1 and express vascular endothelial growth factor 
(VEGF) receptors that have been shown to enhance EC permeability and induce endothelial 
fenestrations [4]. VEGF was first shown to play major role in renal development by 
blocking VEGF activity utilizing an antibody in newborn mice. This resulted in disrupted 
and reduced renal cortical capillary tufts, and an overall reduction in number of nephrons 
[5]. Additional evidence indicates that VGEF is important for EC survival and repair in 
glomerular disease characterized by EC damage [5–7]. Glomerular endothelial fenestrae can 
also be lost within hours following VEGF removal. This results in glomerular endotheliosis, 
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reduction in GFR, and proteinuria [8, 9]. Overexpressoin of VEGF leads to collapsing 
glomerulopathy, further demonstrating that tight regulation of VEGF is critical to 
glomerular development and function [10]. VGEF produced by epithelial cells appears to be 
an important regulator of glomerular EC functionality and permeability. Within the cortex, 
microvascular ECs are fenestrated on those portions of the cell that border tubule epithelial 
cells. Erythropoietin-producing cells are localized in the renal cortical interstitial space 
adjacent to capillary endothelial and tubular epithelial cells. As efferent arterioles from 
juxtamedullary glomeruli penetrate into the outer stripe of the other medulla, the outer 
smooth muscle layer is replaced by a discontinuous layer of pericytes. This marks the 
beginning of the DVR and upon further penetration in to the inner medulla pericytes 
becomes less numerous. In both the inner and outer medullary regions the ascending arterial 
vasa recta outnumber the descending arterial vasa recta. The DVR have a continuous 
nonfenestrated endothelium with a zona occludens limiting their permeability. They express 
both water channels and a facilitated urea transporter[11]. In the inner medullary region, the 
DVR terminate and form a sparse capillary plexus that coalesces to form the AVR. Within 
the AVR EC fenestrations again occur with approximately 50% of the endothelial wall 
covered by fenestrae in the inner medullary region and 15% to 30% in the outer medullary 
region. ECs within the AVR are extremely thin and have remarkably high hydraulic 
conductivity.
Endothelial markers have been determined to differentiate the tremendous heterogeneous 
population of ECs. In human kidney, peritubular capillaries ECs exhibited 
immunohistochemical characteristics similar to those of peripheral macrophages, including 
OKM5 (medullary only), von Willebrand factor (vWF), and interleukin (IL)-1. Glomerular 
capillary ECs expressed vWF but not OKM5. Additional studies have identified RECa-1 and 
JG-12 as pan-EC specific monoclonal antibodies for all the vascular beds in the rat.
Cross talk with pericytes and Peritubular capillaries (PTC)
Pericytes are a type of mural smooth muscle like cell, located to the non-albuminal side of 
EC, which discontinuously encircles the endothelial cells and are embedded in the basement 
membranes of the capillaries (Figure 1). As name indicates, pericytes are perivascular cells. 
Numerous claw like invagination emanating from the cell body of the pericyte encircles 
capillaries, arterioles and venules. They have been identified in many organ and tissues of 
many species [12]. Of the many implicated roles of pericytes vessel stabilization, fibrosis, 
endothelial cell regulation and angiogenesis are the principal ones. Pericytes have been 
molecularly characterized by the presence of an extracellular chondroitin sulfate 
proteoglycan called NG2. Renal pericytes have been demonstrated to express α-smooth 
muscle actin (α-SMA) which is necessary for the regulation of vessels diameter and thus 
renal blood flow [13]. The density of pericytes in kidney is quite heterogeneous. The outer 
medulla has far more pericytes compared to inner medulla [14]. Pericytes and ECs are 
connected bi-directionally via peg and socket junctions. Membrane invaginations from 
pericytes and ECs form tight, gap and adherence junctions. These connections are not mere 
physical contacts but they actively participate to facilitate communication between the two 
cell types [15, 16]. Pericytes have been proposed to acts as a signaling bridge between 
endothelial and peritubular capillaries [17]. The glomerular endothelium essentially lacks 
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stabilization by the loss of crosstalk between ECs and pericytes. Pallone and colleagues have 
demonstrated the role of pericyte in regulating the medullary blood flow by controlling the 
vasa recta capillary diameter [18]. Pericytes detect the vasoactive signals from endothelial 
cells and respond by regulating medullary blood flow via the vasa recta [14, 19]. Various 
endogenous stimuli, acetylcholine [20], angiotensin-II, adenosine triphosphate (ATP), 
endothelin-1, noradrenaline, UTP and vasopressin, have been shown to evoke pericyte 
mediated vasoconstriction of vasa recta. Besides peptides and hormones, free radicals and 
reactive oxygen species (ROS) have also been implicated in the regulation of medullary 
blood flow [21, 22]. All three forms of nitric oxide synthase (endothelial, inducible and 
neuronal) have been identified in tubular and vascular capillaries of kidney [23, 24]. 
Schanackenberg et al. have demonstrated the association of ROS mediated vasoconstriction 
to hypertension and diabetic nephropathy [23, 24]. Similarly, regulation of pericyte 
mediated vasodilation of vasa recta have been demonstrated by acetylcholine (NO 
mediated), adenosine, angiotensin-2 (Ang-2), nitric oxide, PGE2, and vasopressin. In the 
medulla, adenosine acts as vasodilator resulting in increase of medullary blood flow [25, 
26]. Adenosine, which is released from medullary thick ascending limb (mTAL) after 
oxidative stress also dilates vasa recta by acting on pericytes [14]. Dilation of mTAL, that, 
results in increased oxygen supply and simultaneously oxygen consumption, is reduced by 
inhibition of mTAL by NaCl reabsorption [2, 26, 27]. Endothelin-1 (ET-1) synthesized by 
collecting duct epithelial and ECs, is known to constrict DVR by acting on pericytes [14, 
28]. Other vasoactive agents, Ang-II and NO, also act via pericytes [19]. Pericytes along the 
vasa recta have been shown to contract and relax when acted upon by nucleotides released 
from endothelial cells, ATP and UTP, respectively [14, 29, 30]. Kidney slices exposed to 
hypotonic solution release ATP resulted in vasodilation of vasa recta providing direct 
evidence of tubulo-vascular cross talk in the medulla [19].
Pallon et al. have hypothesized that “feedback of vasoactive stimuli to juxtamedullary 
resistance vessels may provide the medulla with an intrinsic feedback loop, which could 
allow the medulla to control its own perfusion” [17, 18]. To summarize, pericytes acts as 
sensor of the extracellular environment and respond accordingly either by constricting 
and/or dilating the microvasculature thus fine tuning the medullary blood flow.
Role of pericyte in endothelium stability
Although the role of ECs in regulation of blood flow and vessel fate has been well studied, 
only recently did the role of pericytes in relation to ECs start to emerge. Pericytes have been 
demonstrated to regulate microvascular stability in central nervous system. In the absence of 
pericytes the brain forms micro-aneurysms and undergoes spontaneous hemorrhage [31]. 
They are also vital in the formation of blood-brain and blood-retina barriers. Diabetic 
retinopathy is characterized by loss of pericytes [32]. Under physiological conditions, two 
signaling pathways have been shown to play key roles in stability and vessel development. 
First, platelet derived growth factor-B/PDGF receptor-β (PDGFR-β) and angiopoietin-Tie2 
are important for pericyte differentiation, recruitment and expansion. Second, transforming 
growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), Notch and 
sphingosine-1-phosphate (S1P) are known to regulate stabilization of vessels [33–35]. In 
pathophysiological conditions, like AKI-induced sepsis or ischemia-reperfusion (IR) injury 
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pericytes are activated, detach from peritubular capillaries [36], migrates to the interstitium 
and differentiate into myofibroblasts [37]. Detachment of pericytes from the endothelium 
results in unstable, proliferating and non-specific permeability of the endothelium. Injury to 
the endothelium ultimately results in loss of microvasculature – also known as rarefaction. 
Thus, pericyte detachment form endothelium has a two prong effect on renal disease 
progression. First, conversion of pericyte into microfibroblasts leads to fibrosis and, second, 
leaky endothelium contribute to the inflammation cascade and oxidative stress [38]. 
Ischemia and oxidative insults to the ECs acts as stimuli for apoptosis as well. In-vitro 
studies have shown that ECs derived from injured kidney show limited growth potential. 
Basile et al. have shown that, even in the presence of excessive VEGF and functional VEGF 
receptor, ECs from injured kidney failed to respond [39]. Lin et al have shown that blockade 
of either PDGFR-β on pericytes or VEGFR2 on ECs prevents pericyte detachment, 
amelioration of fibrosis, stabilization of capillary rarefaction and attenuation of 
inflammatory response [40]. Similarly Greenberg et al. observed that VEGF-A bolstered 
pericytes detachment and microvasculature destabilization via PDGFR-β [41]. Switching 
between three isoforms of VEGF-A (VEGF164, VEGF120, VEGF188) takes place when 
pericytes transform form their normal to myofibroblast type phenotype [40]. In the kidney, 
pericytes to myofibroblast transition is characterized by predominance of VEGF120 and 
VEGF188 that brings about the microvascular rarefaction. Schrimpf et al. have identified two 
genes, tissue inhibitor of metalloproteinase 3 (TIMP3) and a disintegrin and 
metalloproteinase with thrombospondin motifs-1 (ADAMTS1), involved in pericyte 
detachment and regulation [36]. TIMP3, known to promote vascular stability, is lost in 
activated pericyte no longer attached to the endothelium loses that is known to promote. 
TIMP3, an endogenous inhibitor of ADAMTS-1, hastens the loss of microvasculature by 
breaking down the capillary basement membrane and other components of extracellular 
matrix. Additionally, TIMP3 also inhibits the signaling of EC receptor VEGFR2 thus 
preventing pericyte differentiation to myofibroblasts. Kida and colleagues reported another 
mediator, ephrin B4 receptor (EphB4) and its membrane bound ligand ephrinB2, became 
activated in the injured kidney [42]. Lack of ephrinB2 resulted in impaired angiogenesis, 
fibrosis and microvasculature rarefaction. Interestingly, both primary renal pericytes and 
primary renal microvascular ECs showed reduced migration and proliferation in response to 
VGEF-A in ephrinB2 knockouts compared to wildtype. Thus, bidirectional signaling 
between pericytes and the endothelium is indispensable in maintaining normal functioning 
microvasculature [43].
Endothelium in sepsis
The renal vascular endothelium is known to be a primary target in several disease processes 
including glomerular nephritis, vasculitis, lupus nephritis, preeclampsia, hemolytic uremic 
syndrome, ischemic acute renal failure, renal transplantation rejection, and chronic 
progressive kidney disease. During sepsis the immune system is first activated then hyper-
activated leading to an uncontrolled over-whelming immune reaction, which may harm 
rather than protect the organism. In other words, in sepsis we may have “too much of a good 
thing” [44]. Apart from immune cells, ECs are also part of the first line of defense and are 
“activated” in various patho-physiological conditions. ECs are both “victim and perpetrator” 
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in the sepsis. First, they are hyper-activated in the presence of pro-inflammatory cytokines 
and then later ECs undergo structural and functional changes that further sustain the ongoing 
septic process.
An increase in the renal vascular resistance (RVR) is another key hemodynamic factor 
associated with sepsis-induced AKI as increased in RVR have been shown to alter global 
and regional blood flow [45]. Increase RVR can be induced by vasoconstriction, leaky 
endothelium, tissue edema, leukocyte adhesion to ECs and microthrombosis [46]. The 
kidney is a unique organ where two capillary beds, glomerular and peritubular, are joined by 
an arteriole. Thus the kidney can be viewed as many different vascular compartments 
connected in series with separate circuits for each compartment (Figure 3). Injury events, at 
any given place in this series can act as a bottleneck and contribute significantly to the RVR. 
This also suggests that the renal microcirculation and macro-circulation are inherently 
connected and dependent on each other. Increases in either cortical or medullary vascular 
resistance may play role in observed the microvascular alterations. Doppler waveform has 
been used during the initial evaluation of renal dysfunction [47]. The Doppler resistive index 
(RI) described by Pourcelot is widely used as indicative of vascular resistance.
Sepsis involves activation of both innate immune cells such as natural killer cells, natural 
killer T cells, neutrophils, macrophages, and dendritic cells as well as adaptive immune 
CD4+ T cells. Most of the immune cells are detrimental but recent reports have suggested 
protective role of CD4+FoxP3+ regulatory cells, also called as Tregs [48–50]. During 
inflammation, pro-inflammatory mediators secreted by immune cells interact with EC and 
change their physiologic functions. During infectious conditions, activated leukocytes must 
transmigrate to infectious sites to engulf, phagocytose, and destroy invading microbes. This 
is an active process not only for the migrating leukocytes but also for the ECs. During this 
process numerous pro and anti-inflammatory mediators lead to activation of the endothelium 
and result in the expression of various adhesion molecules, which in turn facilitate or inhibit 
the transmigration of activated leukocytes into tissues. In addition, ECs can generate their 
own inflammatory mediators and express adhesion molecules. The hallmark of these disease 
processes is glomerular and renal microvascular EC injury with associated apoptosis. 
Microvascular endothelial damage is the salient feature associated with acute vascular 
rejection and, in chronic allograft nephropathy, the single most common cause of long term 
graft loss [8]. Lipopolysaccharide (LPS) and Toll-Like-Receptor (TLR) interaction are 
important mediators in sepsis. LPS and its cognate LPS-binding protein (LBP), exert their 
biological activity via CD14. LPS/LBP/CD14 complexes are known to activate ECs [51]. 
Regulated by a variety of pro- and anti-inflammatory mediators, EC express TLR4, which, 
when bound to LPS, leads to activation of ECs during the course of sepsis. Further studies 
have revealed binding of β2 integrins (CD11/CD18) to LPS [52]. This complex, consisting 
of CD11/CD18-LPS, can further activate ECs.
Under physiologic conditions EC perform several functions to maintain homeostasis. ECs 
normally inhibit blood coagulation and minimize the adherence of circulating cells. Further, 
by producing prostacyclin, nitric oxide (NO) and other vasoactive substances, EC inhibit 
platelet aggregation and regulate the tone of arterioles and venules, there by regulating the 
microcirculation. Tight regulation of the immune and inflammatory system is crucial for 
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maintaining the balance between protective and tissue-damaging responses. Sepsis is 
characterized by a loss of this balance leading to hyperactive and often followed by 
hypoactive immune and inflammatory responses. During inflammatory states ECs come in 
contact with a variety of proinflammatory mediators that change their physiologic functions 
profoundly. This is collectively considered as “EC activation ”. As a result an interaction 
with and adhesion of leukocyte with ECs is facilitated, ECs switch from an anticoagulant 
state to procoagulant state, and an altered barrier function of ECs leads to increased 
permeability and impaired vasomotor tone. These changes are discussed in detail in 
following sections.
Activation of Inflammation
One of the main underlying mechanisms leading to a state of immune system 
hyperactivation involves the production and release of pro- and anti-inflammatory mediators 
(chemokines and cytokines). Chemokines are involved in attracting neutrophils to the site of 
inflammation, activating leukocytes after the initial rolling, and facilitating their 
transendothelial migration. Endothelial and epithelial cells, as well as neutrophils, 
macrophages, and lymphocytes, produce large amounts of proinflammatory cytokines (e.g., 
TNF-α, IL-6, IL-1β, and IL-8).
TNF-α, which appears to be mainly synthesized in activated macrophages/monocytes, is a 
very early proinflammatory cytokine produced during sepsis and other renal disease state. 
Binding to its receptor leads to cell activation via nuclear factor (NF)-κB transcription 
factor. TNF-α stimulates neutrophils and ECs to release a variety of proinflammatory 
mediators [53]. The IL-1 family (IL-1α, IL-1β) represents another important series of 
cytokines produced during sepsis. IL-1 and TNF-α lead synergistically to further activation 
of the inflammatory cascade and upregulation of vascular adhesion molecule. The 
chemokines IL-8 and monocyte chemoattractant protein (MCP)-1 are additional 
proinflammatory components during sepsis [54]. Released by ECs, IL-8 plays a key role in 
neutrophil chemotaxis and degranulation, whereas EC-derived MCP-1 is involved in 
attracting monocytes. Taken together, production of strong proinflammatory mediators, and 
increased expression of vascular adhesion molecules, lead to a state of endothelial 
hyperactivation. Intracellular pathways become activated, more proinflammatory cytokines 
and chemokines are released, and neutrophils are attracted to the site of inflammation. 
Neutrophils release granular enzymes, ROS (such as H2O2), and NO, that are capable of 
causing increased vascular permeability, tissue damage and, ultimately, organ injury.
Structural changes
During inflammation specific adhesion molecules are expressed on WBC, ECs and platelets. 
Three families of cell adhesion molecules (CAM), the selectins (E, P, L), the integrins ( 1, 
2), and the immunoglobulin superfamily intercellular adhesion molecule (ICAM-1) and 
vascular adhesion molecule (VCAM-1) are expressed on leukocytes, ECs, and platelets play 
important roles in leukocyte-endothelial interactions. Sepsis-induced AKI is associated with 
reduced blood flow enhancing leukocyte to margination and rolling along the surface of 
blood vessels. Rolling and subsequent loose adhesion are facilitated by two interactions. 
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First, L-selectin present on leukocytes and its respective ligands on endothelial cells 
including CD34 and glycosylation dependent cell adhesion molecule (GlyCAM-1). Second, 
E-selectin present on endothelial cells and its corresponding ligand, sialyl Lewis X 
compounds (sLeX) (NeuAc 2–3Gal 1–4[Fuc 1–3]GlcNAc 1 on leukocytes. L-selectins are 
constitutively expressed on leukocytes and shed upon EC activation by membrane bound 
serine proteases. On the contrary, E-selection are expressed only upon activation of EC and 
facilitates the adhesion of leukocytes to ECs. Synthesis of E-selectins are mediated by pro-
inflammatory mediators like TNF- and IL-1 or lipopolysaccharides (LPS). Under 
physiological conditions, P-selectins are stored intracellularly in blood platelets and within 
Weibel-Palade bodies in endothelial cells. Upon EC activation, Weibel-Palade bodies fuses 
with cell membrane and P-selectins move to the cell surface membrane rapidly. P-selectins 
of EC bind to their corresponding ligand, P-selectin glycoprotein ligand (PSGL-1) 
facilitating adhesion of leukocytes to ECs.
Leukocytes after firmly adhering to the endothelium, transmigrate through ECs aided by 
platelet-endothelial cells adhesion molecule (PEACM)-1. Platelets and ECs expressed 
PECAM-1 is mostly localized at the junction of ECs. Antibodies against PECAM-1 has 
been shown to be effective in the migration of leukocyte in vitro [55] and in vivo [56]. 
Thereafter, leukocytes finally migrate into the surrounding interstitial tissue space.
Coagulation
Under physiological conditions ECs inhibit blood coagulation by activation of protein C, 
expression of thrombomodulin [57], specific proteoglycans [58] and release of tissue 
plasminogen activator [59]. Activation of coagulation is central to microcirculatory 
dysfunction. Activated EC under septic conditions play key role in the coagulation. 
Endothelium cell protein C receptor (EPCR) binds to protein C (PC) on the EC and presents 
it to the thrombin-thrombomodulin complex. PC is cleaved and activated by thrombin aided 
by thrombomodulin [60]. Activated protein C (aPC) possesses profibrinolytic, anti-
inflammatory, and antiapoptotic properties and it counter-acts the effect of thrombin and 
pro-inflammatory cytokines helping to restore homeostasis [61, 62]. During inflammation 
expression of naturally occurring anticoagulant and mediators of the PC pathway decrease in 
turn resulting in decreased anti-inflammatory effects. Exposure to either bacterial 
components (e.g., lipopolysaccharide) and/or pro-inflammatory cytokines (e.g., TNF-, IL-1) 
damages ECs, which later undergo apoptosis, thus further amplifying the coagulation 
cascade. In concert with decreased activation and expression of protein C, the extrinsic 
pathway of coagulation also becomes activated. This results in increased microvascular 
coagulation and a further dysfunctional endothelium. Activated protein C has been shown to 
mitigate LPS-induced AKI effects and down regulate renal inducible nitrogen synthase 
(INOS) and angiotensin 2 [62]. Dysfunctional microvascular perfusion, increased vascular 
permeability and coagulation have been shown to be ameliorated by administration of 
soluble thrombomodulin [63]. During sepsis-induced AKI and ischemia reperfusion injury 
the complement pathway undergoes activation and the plasma level of complement 
inflammatory mediators, C3a and C5a, is increased. Both C3a and C5a bind to their 
respective C3a and C5a receptors, belonging to the rhodopsin family of G-protein coupled 
receptors, on renal tubular epithelial cells and granulocytes [64]. This interaction leads to the 
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upregulation of proinflammatory cytokines promoting ischemic injury and further bringing 
more leukocytes in to the interstitium. In addition, C3a and c5a causes renal EC activation 
especially in the S3 segments of the cortical medullary region [65]. C5a has been shown to 
induce the expression of P-selectin on the surface of human umbilical vein ECs (HUVECs) 
and binds to ECs as well [66, 67]. Laudes et al. have shown the ability of C5a to bind to ECs 
[66]. Furthermore, they showed that exposure of mouse dermal microvascular ECs 
(MDMECs) to LPS, IL-6 and interferon (IFN)-resulted in increase C5aR, and incubation 
with C5a and IL-6 led to increased levels of proinflammatory mediators. These data indicate 
tht C5aR can be upregulated on ECs and that C5a in the copresence of additional agonists 
may mediate proinflammatory effects of the endothelium.
Permeability
The endothelium is natural barrier between intravascular and extravascular spaces. ECs are 
not a passive control system but they are actively engaged in blood-tissue exchange of 
plasma fluid, proteins and cells. They are also involved in maintaining vasomotor tone and 
vascular permeability.
Dysfunctional microvascular permeability results from injury to endothelial cells, actin 
cytoskeleton alteration, endothelial cell-cell junctions dissociation, and up-regulation of 
leukocyte-endothelial interactions.
Normal ECs form a continuous semipermeable barrier whereas activated ECs may loose 
their barrier function resulting in increased permeability. Much of our current knowledge 
regarding the endothelial cell-cell junctions comes from in-vitro studies. Two photon in-vivo 
studies have shown the role of MMP-2 and MMP-9 in maintaining the endothelial barrier. 
Activation of these two metalloproteinase is correlated with an increase in microvascular 
permeability [68]. Two pathways, transcellular and paracellular, defines the endothelial 
permeability. Transcellular permeability, mediated via a specialized vesicles containing 
caveolin-1 called caveoli, contributes to the basal permeability of endothelium. The 
paracellular pathway, allowing flow of plasma, proteins and cells through endothelial cell-
cell junctions, is a major contributor under pathophysiological conditions. The integrity of 
endothelial barrier is primarily defined by tight and adherens junctions. Briefly, tight 
junctions are made up of three major transmembrane proteins, claudins, occludins and 
zonular occludins (ZO-1 and ZO-2) which form a zipper like structure at the junctions. 
Adherens are made up of a transmembrane protein, vascular endothelial cadherin (VE-
cadherin), consisting of an extracellular domain that binds homophilically with another VE-
cadherin and intracellular domain associated with actin binding proteins called catenins (α, 
β, γ and p120 catenins). Catenins also serve as mediators in the intracellular signaling 
pathway which modulate the cytoskeletal structure. Numerous intracellular signaling 
mediators including cytosolic calcium, protein kinase C, tyrosine kinases, Rho GTPases, 
cAMP and phosphoinositides play key roles in regulation of the actin cytoskeleton [69–74]. 
Depletion of adenosine triphosphate (ATP) and exposure of oxidants like H2O2 to ECs have 
been demonstrated to alter the actin cytoskeleton. [75–77]. Depletion of ATP results in 
disruption of basal and normal level of F-actin in ECs [78, 79]. Similar observations have 
been made in renal tubular epithelial cell where depletion of ATP results in breakdown of 
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larger cortical F-actin to smaller non-functional aggregates [79]. Interestingly, in activated 
EC, paracellular permeability has been shown to increase through contraction of actin stress 
fiber [80, 81]. Dysregulation of focal adhesion transmembrane proteins, focal adhesion 
kinase (FAK), talin and paxillin, which tethers the ECs to the extracellular matrix also 
contributes to endothelial permeability [82]. Dysfunctional endothelium in 
pathophysiological conditions results in increased permeability allowing hemoconcentration 
due to the outflow of plasma water that leads to stasis and compromised perfusion especially 
in corticomedullary junction [83]. Hemoconcentration, in turn, increases the endothelial-
leukocyte interactions which initiate inflammatory cascade leading to further dysfunction of 
the endothelial permeability barrier[84]. Although an interaction between EC and leukocyte 
has been shown to play a key role in endothelium dysfunction, surprisingly, increased 
endothelial permeability during ischemia-perfusion has been demonstrated to occur in the 
absence of leukocytes [85].
Therapeutics
Sepsis accounts for more death in United States than myocardial infarction [86]. Sepsis 
combined with acute kidney injury is associated with a 70% mortality rate [87]. Though 
substantial progress has been made in the understanding of the sepsis-related acute kidney 
injury, mortality remains unacceptably high. Recent strategies include the neutralization of 
bacterial products, targeting undesirable proinflammatory responses, addition of immuno-
stimulatory agents to restore the immune system, reducing endothelial cells and leukocyte 
interactions, and correction of abnormal coagulation system. Here we focus on therapeutic 
strategies directed towards microvascular endothelial cell activation and dysfunction. 
Restoring a functional endothelial barrier is of utmost importance in sepsis related renal 
injury.
VEGF upon binding with it cognate receptor VEGFR2 is well known to increase vascular 
permeability resulting in a leaky endothelium. An inhibitory VEGFR2 antibody has been 
shown to decrease hantavirus-directed EC permeability in vitro [88]. Two FDA approved 
VEGF2 inhibitors, pazopanib and dasatinib, decrease vascular permeability via 
internalization of the surface adhesion molecule, VE-cadherin [89]. Anti-VEGF antibodies 
to neutralize VEGF are being evaluated in an ongoing clinical trial [90]. Sphingosine-1-
phosphate (S1P) binds to the G-protein coupled receptor, activates integrins, increases 
cortical actin formation thus contributing significantly towards the stability of the 
microvasculature [91–95]. The S1P receptor agonist, FTY720 has been shown to induce β-
catenin and localize VE-cadherin and improve EC permeability [96–99]. Jones et al. have 
recently shown that binding of an endothelial receptor, Robo4, to its cognate ligand Slit 
stabilizes the vascular network by inhibiting endothelial permeability and angiogenesis 
[100]. Further, it was demonstrated that blockade of Robo4 dependent Slit signaling inhibits 
inflammation induced endothelial permeability [101]. Slit-Robo4 modulates endothelial 
permeability by blocking Arf6 activity [102] and regulating the actin cytoskeleton [103]. 
Very recently, Zhu et al. elucidated a novel cytokine mediated pathway involved in EC 
barrier stability. They showed that interleukin receptor-1β activates a MYD88-ARNO-ARF6 
cascade to disrupt vascular stability [104]. SecinH3 which targets the MYD88-ARNO-ARF6 
pathway, has been shown to ameliorate leaky endothelium [100]. Angiopoietin-1 has been 
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identified as an anti-permeability and anti-inflammatory agent. Ang-1 strengthens the 
endothelial cell junctions and downregulates the expression of cell surface adhesion 
molecule like VCAM-1 and E-selectin [105–107]. Ang-1 and its endothelial specific 
receptor tyrosine kinase, Tie2, axis have been actively investigated as potential drug targets 
to decrease the complications associated with inflammation. Kim et.al have demonstrated 
that COMP-Ang-1 decreases LPS induced AKI [108]. A synthetic Tie2 agonist, vasculotide, 
protects against vascular leakage and brings down the mortality rate in murine abdominal 
sepsis [109]. Excess of Angiopoietin-2 (Ang-2), a functional antagonist of Ang-1, has been 
shown to contribute significantly to pulmonary vascular leakage during sepsis [110], AKI 
and multiple organ dysfunction syndrome [111]. Ang-2 has been postulated to “sensitize” 
ECs to TNFα thus aiding in induction of inflammation [112]. In CLP and LPS induced 
Ang-2+/− heterozygous septic mice were relatively protected against AKI, leaky 
endothelium and acute lung injury compared to wild type littermates [113]. Use of statins 
and HMG-CoA reductase inhibitors, has been explored to downregulate P-selectin [114] and 
ICAM-1 expression by endothelial cell [115] and NFκB dependent gene expression to 
reduce inflammation [116]. Our group, using hypoperfusion model of ischemic kidney 
injury and two-photon microscopy, have shown that administration of a variant soluble 
thrombomodulin (sTM F376L) significantly improved microvascular erythrocytes flow 
rates, reduced microvascular endothelial leukocyte rolling and attachment, and minimized 
endothelial permeability[63].
Conclusion
The kidney microvasculature is a complex series of linked domains with extreme 
environmental variations best demonstrated by changes in oxygenation and osmolality from 
the cortex to the outer medullary region. It serves to deliver oxygen and substrates and 
covey reabsorbed compounds and hormonal responses from the kidney. It is positioned 
anatomically and functionally as a crossroad for communication between the tubular 
epithelium and immune systems. The overall complexity has limited our understanding to 
date, but it is well recognized to play major primary or secondary roles in the events leading 
to initiation, maintenance and recovery of acute kidney injury from multiple conditions. 
Multiple molecular pathways have been identified as potential therapeutic targets in animal 
models, yet no translation of this has occurred to man. Furthermore, loss of the 
microvasculature network has been linked to progressive loss of kidney function. Therefore, 
a further understanding of the complexity, responses to stimuli and potential therapeutic 
agents of the kidney microvasculature is necessary if progress in AKI and CKD is to be 
made.
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Schematic representation of the visional difference in the microvasculature within the 
kidney. OSOM, outer stripe of the outer medulla; ISOM, inner stripe of the outer medulla; 
IM, inner medulla; PCT, proximal convoluted tubule; PST, proximal straight tubule; DLT, 
descending thin limb; DCT, distal convoluted tubule; CCD, cortical collecting duct; OMCD, 
outer medullary collecting duct; IMCD, inner medullary collecting duct; AA, arctuate artery; 
IA, interlobular artery. (Reprinted with permission from Endothelial Biomedicine, Ed. 
William C. Aird, 2007, Cambridge University Press, Chapter 138, Pg. 1271).
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Schematic representation of the different forms of ECs found within the peritubular 
microvasculature of the kidney in the different zones of the kidney. (Reprinted with 
permission from Pallone TL, Turner MR, Edwards A, Jamison RL. Countercurrent exchange 
in the renal medulla. Am J Physiol Regul Inter Comp Physiol. 2003;284:R1153-R1175)
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Kidney depicted as multiple vascular compartments connected in series with parallel 
components in each compartment. The total vascular resistance is equal to the sum of 
vascular resistances within the different compartments. Also shown, the associated disease 
conditions/syndromes within each compartment.
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Table 1
Function of Renal endothelium (Modified from Endothelial Biomedicine, Ed. William C. Aird, 2007, 
Cambridge University Press, Chapter 138, Pg. 1271).
Blood Vessel Smooth Muscle Cells Endothelium Major function
Afferent arteriole Continuous Regulate single nephron blood flow
Glomerular capillary Continuous, fenestrated, no 
diaphragm
Selective filtration of macromolecules based on size and 
charge
Efferent arteriole Discontinuous Regulate filtration fraction
Peritubular plexus Fenestrated facing epithelial 
cells
Handle bulk of reabsorbed H2O and ions
DVR Discontinuous pericyte Continuous, nonfenestrated Countercurrent exchanger serving to prevent washout of 
osmotic gradient created by loops of Henle: enters 
increasingly hyperosmolar medulla, thus gains solutes and 
loses water
AVR Discontinuous pericyte Continuous, highly fenestrated, 
diaphragm
Countercurrent exchanger serving to prevent washout of 
osmotic gradient created by loops of Henle: leaves high 
osmolar environment as it moves towards cortex, thus 
loses in DVR and gains back water; net effect is the 
osmolality of blood at end of AVR approaches that of 
blood at beginning of DVR (slightly higher NaCl)
(Modified from Endothelial Biomedicine, Ed. William C. Aird, 2007, Cambridge University Press, Chapter 138, Pg. 1271).
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